STOCKS TELEGRAPH

Tag: ALT stock

  • Here is why Altimmune Inc (ALT) stock sink on Tuesday?

    Here is why Altimmune Inc (ALT) stock sink on Tuesday?

    Altimmune Inc. (ALT) shares plummeted 38.18% in after-hours on Tuesday, June 29, 2021, and closed at $9.83 per share. Earlier in the morning session, ALT’s stock lost 2.45% to close Tuesday’s session at $15.90. ALT shares have risen 52.59% over the last 12 months, and they have moved up 2.19% in the past week. Over the past three months, the stock has gained 17.34%, while over the past six months, it has lost 43.24%.

    The disappointing outcome of AdCOVID™ Phase 1 Clinical Trial

    On June 29, 2021, Altimmune, Inc provided an update on its AdCOVID investigational vaccine for the prevention of COVID-19. The Company also provided an update on its T-COVID Phase 1/2 clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19.

    80 healthy adult volunteers between the ages of 18 and 55 took part in Phase 1 AdCOVID clinical trial. The volunteers received either 1 or 2 doses of AdCOVID as a nasal spray at 3 dose levels.

    The data showed lower than expected immune responses for each of the immune parameters tested. The magnitude of the response and the percent of subjects responding to AdCOVID were substantially lower than what had been demonstrated for other vaccines already authorized for emergency use.

    Due to poor trial 1 results, Altimmune is discontinuing further development of AdCOVID beyond the completion of this Phase 1 trial.

    Positive Interim Data from ALT-801 Phase 1 Trial

    On June 16, 2021, Altimmune, Inc announced results from a prespecified 6-week interim analysis of its ongoing 12-week, Phase 1, placebo-controlled, single and multiple ascending dose trial of ALT-801, an investigational GLP-1/glucagon dual receptor agonist, in healthy overweight and obese volunteers. The study is currently being conducted in Australia under a clinical trial application.

    The results showed that a mean weight loss of 5.4% was achieved by Week 6 with a once-weekly ALT-801 dose of 1.8 mg compared to a weight gain of 0.9% in the placebo group.

    Recent financial results

    On May 17, 2021, Altimmune, Inc released its financial results for the three months ending March 31, 2021.

    Q1 2021 financial highlights

    • Altimmune reported revenue of $0.8 million for Q1 2021 compared to $2.2 million inQ1 2020.
    • The company spent $11.9 million in research and development expenses in Q1 2021 compared to $7.2 million in Q1 2020.
    • General and administrative expenses were $3.8 million in Q1 2021 compared to $2.3 million in Q1 2020.
    • The company suffered a net loss of $14.9 million, or $0.38 net loss per share in Q1 2021, compared to $3.9 million, or $0.26 net loss per share in Q1 2020.
    • As of March 31, 2021, Altimmune had cash, cash equivalents, and short-term investments totalling $226.5 million compared to $216.0 million on December 31, 2020.

    Conclusion

    The poor trial one results of the Covid-19 vaccine candidate took the ALT stock to rock bottom. The plummeting can continue on Wednesday as well.

  • Early Morning Vibes: Check Out These 4 hot Stocks Right Now

    Early Morning Vibes: Check Out These 4 hot Stocks Right Now

    On December 24, American stock indices closed in the green. The S&P 500 Index climbed 0.35% to 3690 points, the Dow Jones added 0.23%, the NASDAQ 0.29%. The news background on the eve of Christmas was weak. Fiscal stimulus prospects continued to be supportive. The tech sector was one of the growth leaders with 0.75%, while the energy sector looked the weakest and lost 0.63%.

    Corporate news

    The State Administration for Market Regulation of the People’s Republic of China has suspected Alibaba Group (BABA: -13.4%) of violating antitrust laws. At the same time, the People’s Bank of China demands to reform the business of the fintech division of Alibaba Ant Group.

    The FDA has paused clinical trials for an anti-clotting vaccine developed by Altimmune (ALT: -9.3%) and is demanding additional data. 

    Today, world stock markets are showing mostly positive dynamics. On Sunday, December 27, President Donald Trump signed into law a $ 900 billion economic support bill that will include a one-time payment of $ 600 per person to Americans. Earlier, the president insisted on increasing the amount of payments to $ 2,000. A vote in Congress on this issue will take place today. If approved, this measure will be included in a separate bill. However, it is unlikely that the Republicans will support the initiative. Trump’s approval of the stimulus package is positive for the stock market, but some of these expectations have already been incorporated into quotes, and no new stimulus is expected in the short term. Thus, market response to these developments will be very limited, especially given the reduced volatility and trading volumes.

    Investors’ attention from the stimulus package will gradually shift to the front of the fight against coronavirus. According to US chief infectious disease specialist Anthony Fauci, “the worst” is yet to come, as the holidays will trigger a surge in COVID-19. However, most of all investors are now interested in the rate of vaccination of the population, because if it does not correspond to the original plans, it will lead to a correction in cyclical sectors.
    Technical picture

    Technically, the S&P 500 is prone to consolidation. The trading session the day before did not change the overall picture. Volatility will remain low ahead of the New Year. The RSI and MACD indicators continue to form bearish divergence, so the risk of correction remains.

    Today Top Movers‎

    ‎NXT-ID Inc (NXTD)‎‎ is up 42.74% at $1.77 in premarket trading session on Monday.‎

    ‎Ocugen, Inc (OCGN)‎‎ reported an increase of 44.32%, with the share price at $2.54 in today’s premarket trading session following the appointment of a vaccine scientific advisory board.‎

    ‎Jaguar Health Inc (JAGX)‎‎ share price gained 21.67% at $0.87 in early morning trading session on Monday. The firm recently signed second agreement for $6 million non-dilutive financing transaction involving the sale of royalty rights related to future Mytesi (Crofelemer) and Lechlemer revenue stream.

    ‎‎Naked Brand Group Ltd (NAKD)‎‎ share price soared 1.91% at $0.21 on Monday during premarket trading session after declaring that it has been granted an additional 180-day period, or until May 24, 2021.‎

    Latest Insider Activity


    Workhorse Group Inc. (WKHS) Director Chess Raymond Joseph announced the sale of shares taking place on Dec 18 at $21.05 for some 5,000 shares. The total came to more than $0.11 million.
     

    Invitae Corporation (NVTA) President & CEO George Sean E sold on Dec 22 a total 631,018 shares at $53.06 on average. The insider’s sale generated proceeds of almost $0.19 million.
     

    Neoleukin Therapeutics Inc. (NLTX) Director BAKER BROS. ADVISORS LP declared the purchase of shares taking place on Jul 07 at $15.25 for some 424,000 shares. The transaction amount was around $6.47 million.
     

    Odonate Therapeutics Inc. (ODT) Chief Executive Officer TANG KEVIN C bought on Dec 23 a total 15,514,566 shares at $15.58 on average. The purchase cost the insider an estimated $2.17 million.

    Earnings To Watch

    Top US earnings releases scheduled for today include Secoo Holding Limited (NASDAQ:SECO). It will announce its Jun 2019 financial results. The company is expected to report revenues of $241.41M in the three-month period.

  • Pre-Market Cues: 32 Stocks Roaring for Change On December 1st

    Pre-Market Cues: 32 Stocks Roaring for Change On December 1st

    China Automotive Systems Inc. (CAAS) stock soared 2.38% to $10.75 in the pre-market trading after reporting that it shipped approximately 120,000 units from its portfolio of electric power steering products for use in Chinese electric vehicles during 2020. The most recent rating by Brean Murray, on August 15, 2011, is a Hold.
    Before the trading started on December 01, 2020, G1 Therapeutics Inc. (GTHX) is up 4.05% to reach $19.0. It has been trading in a 52-week range of $8.80 to $31.38.
    Sundial Growers Inc. (NASDAQ: SNDL) shares are trading up 29.83% at $0.947 at the time of writing following the announcement its elimination of senior secured second lien convertible notes. Company’s 52-week ranged between $0.14 to $3.88.
    Jaguar Health Inc. (JAGX) grew over 69.45% at $0.5929 in pre-market trading today.
    SuperCom Ltd. (SPCB) stock moved down -10.74 percent to $1.08 in the pre-market trading and the company recently declared that it has secured a contract to provide its PureSecurity Electronic Monitoring (EM) suite in Wisconsin.
    MicroStrategy Incorporated (NASDAQ: MSTR) shares are trading up 4.93% at $359.66 at the time of writing. Company’s 52-week ranged between $90.00 to $280.00. Analysts have a consensus price target of $200.
    Veritone Inc. (VERI) grew over 4.4% at $27.78 in pre-market trading today after announcing that it now supports NVIDIA CUDA for GPU-based AI and machine learning.
    Before the trading started on December 01, 2020, Creative Realities Inc. (CREX) is down -7.26% to reach $1.15. It has been trading in a 52-week range of $0.52 to $5.98.
    Moderna Inc. (MRNA) stock soared 10.32% to $168.5 in the pre-market trading after declaring that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The most recent rating by Wells Fargo, on November 23, 2020, is an Equal weight.
    VBI Vaccines Inc. (VBIV), a Biotechnology company, rose about 3.94% at $3.56 in pre-market trading Tuesday.
    Schultze Special Purpose Acquisition Corp. (SAMA) stock moved up 2.86 percent to $12.6 in the pre-market trading after reporting effectiveness of registration statement for proposed business combination with Clever Leaves International Inc.
    Celsion Corporation (CLSN) gained over 5.59% at $0.71 in pre-market trading Tuesday December 01, 2020.
    Nano-X Imaging Ltd. (NNOX) is up more than 5.22% at $64.5 in pre-market hours Tuesday December 01, 2020. The healthcare firm lately announced revised time of live demonstration at the 2020 radiology society of North America virtual annual meeting. The stock had jumped over 17.21% to $61.30 in the last trading session.
    Before the trading started on December 01, 2020, Greenlane Holdings Inc. (GNLN) is up 2.89% to reach $4.27. It has been trading in a 52-week range of $1.02 to $4.20.
    Mogo Inc. (MOGO) stock soared 3.77% to $2.75 in the pre-market trading. The firm recently declared the release of its new updated Mogo app featuring an interactive Rainforest Mode as part of the MogoCard experience. The most recent rating by Raymond James, on July 23, 2020, is an Outperform.
    Altimmune Inc. (NASDAQ: ALT) shares are trading up 9.57% at $13.4 at the time of writing. Company’s 52-week ranged between $1.60 to $35.10. Analysts have a consensus price target of $28.
    Novavax Inc. (NVAX) grew over 6.09% at $148.0 in pre-market trading today following publication its COVID-19 vaccine clinical development progress.
    Marathon Patent Group Inc. (MARA), a Capital Markets company, rose about 7.96% at $6.78 in pre-market trading Tuesday.
    Aphria Inc. (APHA) is up more than 3.46% at $8.67 in pre-market hours Tuesday December 01, 2020. The healthcare company recently revealed that it has closed the accretive, strategic acquisition of SW Brewing Company, LLC. The stock had jumped over 8.41% to $8.38 in the last trading session.
    AquaBounty Technologies Inc. (AQB) gained over 4.31% at $6.05 in pre-market trading Tuesday December 01, 2020.
    Before the trading started on December 01, 2020, ADMA Biologics Inc. (ADMA) is up 2.45% to reach $2.09 following the announcement its commencement of operations and initiation of collections at its newest ADMA BioCenters plasma collection facility located in Maryville, Tennessee. It has been trading in a 52-week range of $1.45 to $4.95.
    CureVac N.V. (CVAC) is down more than -3.12% at $101.89 in pre-market hours Tuesday December 01, 2020. The stock had jumped over 22.29% to $105.17 in the last trading session.
    OrganiGram Holdings Inc. (OGI) gained over 4.26% at $1.47 in pre-market trading Tuesday December 01, 2020 after releasing its results for the fourth quarter ended August 31, 2020.
    FuelCell Energy Inc. (FCEL) is down more than -3.43% at $9.85 in pre-market hours Tuesday December 01, 2020. The stock had jumped over 5.26% to $10.20 in the last trading session.
    SSR Mining Inc. (SSRM) grew over 2.12% at $18.8 in pre-market trading today. The company lately publicized that positive results of the Çöpler District master plan studies.
    Before the trading started on December 01, 2020, Entasis Therapeutics Holdings Inc. (ETTX) is up 4.35% to reach $1.92. It has been trading in a 52-week range of $1.58 to $5.64.
    Luokung Technology Corp. (LKCO) is up more than 2.93% at $0.6 in pre-market hours Tuesday December 01, 2020 after the firm reported that it won bid for Heilongjiang Institute of Technology (“HIT”) Smart Campus first phase procurement project of USD 1.3 million. The stock had jumped over 4.09% to $0.58 in the last trading session.
    Riot Blockchain Inc. (RIOT) is up more than 3.55% at $8.75 in pre-market hours Tuesday December 01, 2020. The stock had jumped over 35.20% to $8.45 in the last trading session.
    Before the trading started on December 01, 2020, Dada Nexus Limited (DADA) is down -4.28% to reach $55.47 after declaring proposed follow-on public offering of American depositary shares. It has been trading in a 52-week range of $14.60 to $56.91.
    Logitech International S.A. (NASDAQ: LOGI) shares are trading down -3.3% at $87.32 at the time of writing. Company’s 52-week ranged between $31.37 to $95.71.
    Advaxis Inc. (ADXS), a Biotechnology company, rose about 11.86% at $0.33 in pre-market trading Tuesday. The biotechnology firm recently declared closing of $9.2 million public offering.
    Arbutus Biopharma Corporation (NASDAQ: ABUS) shares are trading up 11.26% at $5.04 at the time of writing. Company’s 52-week ranged between $0.88 to $9.02. Analysts have a consensus price target of $8.